ADOPT Phase 4 Interim Analysis: Avatrombopag in Chronic ITP
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, posted on LinkedIn:
”ADOPT Phase 4 interim analysis: Avatrombopag in chronic ITP
Pleased to share this ASH poster as one of the co-authors. The interim dataset provides useful real-world evidence on avarombopag efficacy and safety in clinical practice.
Study overview:
– 199 patients | Mean 9.7 years from ITP diagnosis to enrollment
– 52.3 weeks median avarombopag dosing duration
– 44.1 cumulative weeks with platelet counts ≥30×10⁹/L
– 59.3% had received prior TPO-RA therapy—reflecting a population with established disease
Health-related quality of life outcomes:
→ EQ-5D-5L: improvements in mobility, usual activities, and pain/discomfort from enrollment to month 12
→ FACIT-Fatigue scores: consistent improvement across follow-up
→ WPAI: measurable reductions in work absenteeism, presenteeism, and overall impairment
→ ITP-PAQ: higher scores at month 12 across multiple scales
Safety findings:
18.1% adverse event rate | 12.6% serious AEs | 5.5% treatment-related AEs | 2.0% discontinued due to AEs
The data demonstrates sustained platelet control alongside functional improvements in work and daily activities. This aligns with our broader understanding of how effective haemostatic management translates to patient-reported outcomes.
The full analysis continues. Worth reviewing if you’re managing patients on TPO-RA therapy or evaluating treatment efficacy beyond platelet counts alone. ”
Stay updated with Hemostasis Today.
-
Nov 8, 2026, 19:31Anna Kajaste-Rudnitski: Presenting AAV-Induced p53 Signalling in Human CNS Cells at ESGCT 26
-
Nov 8, 2026, 19:29David McIntosh: Cybersecurity Matters, but Blood Availability Remains the Bigger Challenge
-
Nov 8, 2026, 19:26Wenxue Ma: An Integrative Framework for Macrophage-Mediated Therapeutic Resistance in Cancer
-
Nov 8, 2026, 19:25Yildiz Yigit: Presenting a Polycythemia Vera Case at the MPN Subcommittee Session
-
Nov 8, 2026, 18:56Denis Oduor: Strengthening the Regulation and Delivery of Blood Transfusion and Transplantation Services
-
Nov 8, 2026, 18:28Raghavendra Rao: A Narrative Review on Chronic Venous Disease during Pregnancy
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause
-
Nov 8, 2026, 17:38Nasrin Samadi: Can a Normal Clotting Test Be Misleading?